CT
Chad Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by JONES THOMAS E, was filed 21 Feb 2007.
Chad Therapeutics Inc: what insiders have been doing
This page follows insider dealings at Chad Therapeutics Inc as filed with SEC (Form 4). The past year has been quiet: not a single insider filing for Chad Therapeutics Inc. The previous disclosure was published on 10 July 2008.
The full history, which starts in 2006, counts 6 purchases against 8 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
15
Thresholds
n/a
Buy Volume
€23,231
6 ops. · all time
Sell Volume
€61,143
8 ops. · all time
Financial data
· cache
Last declaration on 10 July 2008
Declarations15 total
- 62,618 shares@ US$0.19Common StockSEC:0001209191-08-042079:0
- 8,046 shares@ US$1.65Common SharesSEC:0001209191-07-014515:0
- 8,046 shares@ US$1.60Common SharesSEC:0001209191-07-013778:0
- 6,419 shares@ US$1.59Common SharesSEC:0001209191-07-012960:0
- 1,470 shares@ US$1.70Common SharesSEC:0001209191-07-012239:0Canonical exit: 22 May 2007 (T+90)
- 5,628 shares@ US$1.67Common SharesSEC:0001209191-07-011868:0
- 2,627 shares@ US$2.87Common SharesSEC:0001209191-07-000404:0
- 8,327 shares@ US$2.40Common SharesSEC:0001209191-07-000404:1
- 1,823 shares@ US$2.99Common SharesSEC:0001209191-06-061420:0
- 650 shares@ US$3.07Common SharesSEC:0001209191-06-061420:1
- 994 shares@ US$3.02Common SharesSEC:0001209191-06-045903:0Canonical exit: 29 Jul 2006 (T+90)
- 1,099 shares@ US$2.73Common SharesSEC:0001209191-06-045903:1Canonical exit: 29 Aug 2006 (T+90)
- 1,070 shares@ US$2.80Common SharesSEC:0001209191-06-045903:2Canonical exit: 28 Sept 2006 (T+90)
- 1,134 shares@ US$2.65Common SharesSEC:0001209191-06-045903:3Canonical exit: 29 Oct 2006 (T+90)
- 10,000 shares@ US$1.53Common SharesSEC:0001209191-06-045903:4Canonical exit: 13 Nov 2006 (T+90)
15 of 15 declarations
About Chad Therapeutics Inc
Chad Therapeutics Inc is a company listed on the XNAS market. It specializes in the development of therapeutic products.
